GW Pharmaceuticals plc and Almirall S.A. today announce the successful completion of the European Mutual Recognition Procedure (MRP) for Sativex® oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS).
Following previous positive regulatory submissions in the UK, Spain, Germany, Italy, Denmark Sweden, Austria, Czech Republic, a MRP application was made to expand the availability of Sativex® to ten additional European countries. The MRP has now closed successfully with regulatory authorities in all ten countries confirming that Sativex® meets their requirements for approval. The countries involved in the MRP and in which Sativex® is expected to be approved are: Belgium, Finland, Iceland, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal and Slovakia.
"For Almirall, the successful completion of this second MRP regulatory process for Sativex® represents very good news and reinforces our commitment to expand this innovative medicine to MS patients across Europe. Sativex® is the first treatment specifically indicated for the treatment of spasticity, and related symptoms, in MS patients" said Bertil Lindmark, Chief Scientific Officer at Almirall....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814
- Similar Topics
- Last post
CCSVI procedure failed...
Last post by jimmylegs « Wed Dec 26, 2018 1:54 pmReplies: 25
Posted in Chronic Cerebrospinal Venous Insufficiency (CCSVI)by ricleal » Mon Nov 19, 2018 1:06 pm » in Chronic Cerebrospinal Venous Insufficiency (CCSVI)
- 25 Replies
- 5287 Views
Last post by jimmylegs
Wed Dec 26, 2018 1:54 pm